- New multi-purpose reactors (4m³ to 12m³) and a 9m³ hydrogenation reactor will be installed.
- Completion of the new equipment installation is expected by Q3 2017.
- A dedicated continuous flow production unit will produce multiple metric tons of high purity intermediates annually.
- The expansion is part of a strategic campaign to invest in small molecule API manufacturing globally.
Expansion of Manufacturing Capacity
Cambrex Corporation has expanded its large-scale manufacturing capacity at its cGMP facility in Karlskoga, Sweden. The expansion includes the installation of new multi-purpose reactors ranging from 4m³ to 12m³ and the upgrading of the control room within an existing plant. This additional capacity enhances the facility's ability to support clients' development projects from R&D through to large-scale commercial manufacturing. The installation of all new equipment, including a 9m³ hydrogenation reactor, is expected to be completed by Q3 2017.
Introduction of Continuous Flow Technology
In addition to the capacity investment, Cambrex has introduced a dedicated continuous flow production unit at the Karlskoga site. This unit is capable of producing multiple metric tons of high purity intermediates per annum. The continuous flow unit leverages Cambrex's extensive experience with continuous flow and high energy chemistry, allowing for greater production efficiency and flexibility.
Strategic Investment Campaign
The expansion at the Swedish site is part of Cambrex's ongoing strategic campaign to invest in small molecule API manufacturing across its global network of facilities. This initiative aims to enhance the company's manufacturing capabilities and better serve its existing and future customers.
